Skip to main content
Equibles
JRSS logo

JRSS · JRSIS HEALTH CARE Corp · Documents

Track JRSS — free

Use JRSS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JRSS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 At close · Oct 15
Rebalance outlook locked
Going-concern doubt — flagged Dec 20, 2024

Substantial doubt about the company's ability to continue as a going concern.

“Management believes these factors raise substantial doubt about the Company's ability to continue as a going concern for the next twelve months. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Dec 20, 2024
Market Cap
$1.10M
Shares
84.60M
Volume · Oct 15 2575 Avg daily vol (8 sessions) 3648

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2023 Revenue $3.46M up 101.4% 10-K filed Apr 26, 2024 Quarterly report FY2024 Q3 Revenue $222.92K down 55.2% 10-Q filed Dec 20, 2024
2024
Apr 26
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $3.46M ▲ 101.4% Net loss $80.91K Diluted EPS -$0.00
2023
Aug 31
Annual report 10-K/A FY2022, ended Dec 31
Annual report for FY2022
Revenue $89.17K Net income $2.33M ▼ 26.8% Diluted EPS -$0.75
Jul 26
Annual report 10-K/A FY2022, ended Dec 31
Annual report for FY2022
Revenue $89.17K Net income $2.33M ▼ 26.8% Diluted EPS -$0.75
Apr 17
Annual report 10-K FY2022, ended Dec 31
Annual report for FY2022
Revenue $89.17K Net income $2.33M ▼ 26.8% Diluted EPS -$0.75
2022
May 20
Quarterly report 10-Q FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Revenue $15.62M ▲ 113.2% Net income $2.64M ▲ 432.1% Diluted EPS $0.10 ▲ 451.1%
Apr 15
Annual report 10-K FY2021, ended Dec 31
Annual report for FY2021
Revenue $44.39M ▲ 24.3% Net income $3.19M ▼ 16.7% Diluted EPS $0.12 ▼ 18.4%
2021
Nov 15
Quarterly report 10-Q FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $12.16M ▲ 21.4% Net income $541.5K ▼ 47.6% Diluted EPS $0.02 ▼ 54.0%
Aug 20
Quarterly report 10-Q FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $11.74M ▲ 67.3% Net income $1.02M ▲ 153.8% Diluted EPS $0.04 ▲ 122.9%
May 14
Quarterly report 10-Q FY2021 Q1, ended Mar 31
Quarterly report for FY2021 Q1
Revenue $7.33M ▲ 22.3% Net income $327.68K ▲ 110.7% Diluted EPS $0.02 ▲ 106.3%
Apr 15
Annual report 10-K FY2020, ended Dec 31
Annual report for FY2020
Revenue $35.71M ▲ 13.5% Net income $2.68M ▲ 201.7% Diluted EPS $0.15 ▲ 177.1%
2020
Nov 13
Quarterly report 10-Q FY2020 Q3, ended Sep 30
Quarterly report for FY2020 Q3
Revenue $10.02M ▲ 29.0% Net income $765.94K ▲ 61.1% Diluted EPS $0.04 ▲ 61.2%
Aug 14
Quarterly report 10-Q FY2020 Q2, ended Jun 30
Quarterly report for FY2020 Q2
Revenue $7.02M ▼ 7.3% Net income $291.22K ▼ 55.5% Diluted EPS $0.02 ▼ 60.3%
Showing 1–50 of 57 documents
Key facts CIK 1597892